You just read:

Isofol Reports 58 % Overall Response Rate in Patients with Metastatic Colorectal Cancer in Phase 1/2a Open Label Extension Study with Arfolitixorin

News provided by

Isofol Medical

May 08, 2019, 11:30 ET